Robert H Vonderheide

Featured in: Favicon

nature.com Favicon

cell.com

thelancet.com Favicon

healio.com Favicon

annualreviews.org Favicon

jimmunol.org

Articles

Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer - Nature

Nov 12, 2024 | nature.com | Alvaro Curiel-Garcia |Margo I Orlen |Clint A. Stalnecker |Julien Dilly |Marie C. Hasselluhn |Stephanie Chang | +16 more

Correction to: Nature https://doi.org/10.1038/s41586-024-07379-z Published online 8 April 2024In the version of the article initially published, in the Data availability section, the GEO accession number was incorrect and has now been amended to GSE252002 in the HTML and PDF version of the article.
Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer - Nature

Apr 8, 2024 | nature.com | Alvaro Curiel-Garcia |Margo I Orlen |Clint A. Stalnecker |Julien Dilly |Marie C. Hasselluhn |Stephanie Chang | +16 more

AbstractBroad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by RAS mutations1,2. RMC-7977 is a highly selective inhibitor of the active GTP-bound forms of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants (RAS(ON) multi-selective)3.
Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma - Nature Communications

Feb 20, 2024 | nature.com | Il-Kyu Kim |Jeffrey Lin |Stacy Thomas |Takeshi Katsuda |John W. Tobias |Robert H Vonderheide

AbstractAcquired resistance to immunotherapy remains a critical yet incompletely understood biological mechanism. Here, using a mouse model of pancreatic ductal adenocarcinoma (PDAC) to study tumor relapse following immunotherapy-induced responses, we find that resistance is reproducibly associated with an epithelial-to-mesenchymal transition (EMT), with EMT-transcription factors ZEB1 and SNAIL functioning as master genetic and epigenetic regulators of this effect.
Ferroptosis of immune cells in the tumor microenvironment

Jun 26, 2023 | cell.com | Devon Taylor |Robert H Vonderheide |Dmitry I Gabrilovich

Cookie Preference CenterWe use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.